{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:07:23Z","timestamp":1772827643875,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan"},{"name":"Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan"},{"name":"the Program for Promotion of Fundamental Studies in Health Science of the National Institute of Biomedical Innovation"},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12282-018-00944-1","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T12:03:20Z","timestamp":1546603400000},"page":"459-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cancer stem-like properties of hormonal therapy-resistant breast cancer cells"],"prefix":"10.1007","volume":"26","author":[{"given":"Kanami","family":"Uchiumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouki","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"944_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/theoncologist.9-4-378","volume":"9","author":"WJ Gradishar","year":"2004","unstructured":"Gradishar WJ. Tamoxifen\u2014what next? Oncologist. 2004;9:378\u201384.","journal-title":"Oncologist"},{"key":"944_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2007.15.0946","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26:798\u2013805.","journal-title":"J Clin Oncol"},{"key":"944_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00000658-198701000-00004","volume":"205","author":"U Veronesi","year":"1987","unstructured":"Veronesi U, Cascinelli N, Greco M, Di Fronzo G, Oriana R, Merson M, et al. A reappraisal of oophorectomy in carcinoma of the breast. Ann Surg. 1987;205:18\u201321.","journal-title":"Ann Surg"},{"key":"944_CR4","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1158\/1078-0432.CCR-10-2920","volume":"17","author":"A Brodie","year":"2011","unstructured":"Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res. 2011;17:4208\u201313.","journal-title":"Clin Cancer Res"},{"key":"944_CR5","doi-asserted-by":"publisher","first-page":"30458","DOI":"10.1074\/jbc.M305226200","volume":"278","author":"LA Martin","year":"2003","unstructured":"Martin LA, Farmer I, Johnston SR, Ali S, Marshall CJ, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278:30458\u201368.","journal-title":"J Biol Chem"},{"key":"944_CR6","doi-asserted-by":"publisher","first-page":"40080","DOI":"10.1074\/jbc.M105892200","volume":"276","author":"RL Stephen","year":"2001","unstructured":"Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem. 2001;276:40080\u20136.","journal-title":"J Biol Chem"},{"key":"944_CR7","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","volume":"23","author":"MC Gutierrez","year":"2005","unstructured":"Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23:2469\u201376.","journal-title":"J Clin Oncol"},{"key":"944_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jsbmb.2013.08.012","volume":"139","author":"N Fujiki","year":"2014","unstructured":"Fujiki N, Konno H, Kaneko Y, Gohno T, Hanamura T, Imami K, et al. Estrogen response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms. J Steroid Biochem Mol Biol. 2014;139:61\u201372.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"944_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J, Gutierrez C, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"944_CR10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/jnci\/djj495","volume":"98","author":"TM Phillips","year":"2006","unstructured":"Phillips TM, McBride WH, Pajonk F. The response of CD24(-\/low)\/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777\u201385.","journal-title":"J Natl Cancer Inst"},{"key":"944_CR11","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"944_CR12","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1073\/pnas.0400067101","volume":"101","author":"C Hirschmann-Jax","year":"2004","unstructured":"Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"944_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555\u201367.","journal-title":"Cell Stem Cell"},{"key":"944_CR14","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/bcr2108","volume":"10","author":"G Honeth","year":"2008","unstructured":"Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, L\u00f6vgren K, et al. The CD44+\/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.","journal-title":"Breast Cancer Res"},{"key":"944_CR15","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/j.1582-4934.2008.00455.x","volume":"13","author":"AK Croker","year":"2009","unstructured":"Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236\u201352.","journal-title":"J Cell Mol Med"},{"key":"944_CR16","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.clbc.2014.11.002","volume":"15","author":"T Ito","year":"2015","unstructured":"Ito T, Sato N, Yamaguchi Y, Tazawa C, Moriya T, Hirakawa H, et al. Differences in stemness properties associated with the heterogeneity of lumimal-type breast cancer. Clin Breast Cancer. 2015;15:e93\u2013103.","journal-title":"Clin Breast Cancer"},{"key":"944_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10549-012-2148-8","volume":"135","author":"RA Gilani","year":"2012","unstructured":"Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2012;135:681\u201392.","journal-title":"Breast Cancer Res Treat"},{"key":"944_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/emmm.201303411","volume":"6","author":"M Piva","year":"2014","unstructured":"Piva M, Domenici G, Iriondo O, R\u00e1bano M, Sim\u00f5es BM, Comaills V, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2014;6:66\u201379.","journal-title":"EMBO Mol Med"},{"key":"944_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jsbmb.2014.08.019","volume":"144","author":"R Fujii","year":"2014","unstructured":"Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014;144:513\u201322.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"944_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsbmb.2016.11.017","volume":"167","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, et al. Different epigenetic mechanisms of ER\u03b1 implicated in the fate of fulvestrant-resistant breast cancer. J Steroid Biochem Mol Biol. 2017;167:115\u201325.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"944_CR21","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-04-3236","volume":"65","author":"Y Yamaguchi","year":"2015","unstructured":"Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 2015;65:4653\u201362.","journal-title":"Cancer Res"},{"key":"944_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10147-015-0788-5","volume":"20","author":"S Hayasgi","year":"2015","unstructured":"Hayasgi S, Kimura M. Mechanisms of hormonal therapy resistance in breast cancer. Int J Clin Oncol. 2015;20:262\u20137.","journal-title":"Int J Clin Oncol"},{"key":"944_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ctrv.2013.09.008","volume":"40","author":"P Mallini","year":"2014","unstructured":"Mallini P, Lennard T, Kirby J, Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev. 2014;40:341\u20138.","journal-title":"Cancer Treat Rev"},{"key":"944_CR24","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","volume":"66","author":"MF Clarke","year":"2016","unstructured":"Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells\u2013perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2016;66:9339\u201344.","journal-title":"Cancer Res"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-00944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-018-00944-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-00944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T19:27:55Z","timestamp":1578079675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-018-00944-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s12282-018-00944-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"18 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Shin-ichi Hayashi received research grants from Novartis Pharma K.K, Astra Zeneca K.K, and Eisai K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}